

GAC and IX Groundwater Treatment Pilot Test Plan

Cape Fear Public Utility Authority

Wilmington, NC January 4, 2019



Table of Contents

Test Plan	2
Introduction	2
General Testing Conditions	3
Equipment Procurement and Setup	3
Test Monitoring	5
PFAS and CEC Cost Considerations and Sampling Schedule	6
Appendix A – Baseline PFAS Results from the Westbrook ASR Well	10
Appendix B – PFAS and CECs	13



Test Plan

Introduction

The Cape Fear Public Utility Authority (Authority) operates an Aquifer Storage and Recovery (ASR) system to supplement their potable water supply through the storage of treated water from the Sweeney Water Treatment Plant (WTP) in the PeeDee Aquifer. The purpose of the Westbrook ASR system is to provide water that can later be withdrawn during peak demand times. The ASR system has a capacity of 1 million gallons per day (mgd). Due to per- and polyfluoroalkyl substance (PFAS) contamination in the Cape Fear River, Sweeney WTP finished water injected into the ASR system can be contaminated with these compounds that are at concentrations greater than the current EPA and NC health advisories that exist for three of these compounds: perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA) and GenX. As a result, the ASR system is not currently in operation and 50,000,000 gallons of groundwater have been withdrawn from the aquifer and disposed. Results of baseline PFAS testing from the ASR well conducted in July 2018 are presented in Appendix A.

As a result, the Division of Water Infrastructure (DWI) of the Department of Environmental Quality (DEQ) has granted the Authority funds, per North Carolina Session Law 2018-5, to perform non-targeted sampling of finished water in its ASR system. Additionally, funds have been provided to determine the relative effectiveness of granular activated carbon (GAC) and ion exchange (IX). To accomplish this task, main pilot trains and mini pilot columns will be evaluated over a three month period according to Table 1.

Table 1. Testing Scenarios

Test Scenarios	Purpose
GAC and IX Main Pilot Trains in Parallel	To evaluate GAC and IX simulating large-scale groundwater treatment.
GAC and IX Mini Pilot Columns in Parallel	To evaluate PFAS breakthrough in GAC and IX processes. Mini pilot columns will be scaled-down versions of the pilot trains.
GAC-IX Mini Pilot Columns in Series	To determine the PFAS removal capabilities of a GAC-IX lead-lag configuration.

This test plan outlines the general testing conditions, equipment procurement and setup, and test monitoring for two main pilot trains and four mini pilot columns located at the Westbrook ASR well. The objective of this investigation will be to evaluate the treatment efficacy of two treatment technologies (GAC and IX), the benefits of GAC and IX processes on water quality, demonstrate the feasibility of implementation, and reduce process and cost risks based on real-time operations.



General Testing Conditions

Per North Carolina Session Law 2018-5, this project, including a final report, must be completed by June 1, 2019. Pilot operation and PFAS sample collection must be completed by the end of March due to the lengthy turnaround time of PFAS results.

It is estimated that the main pilot trains and mini pilot columns will begin operation on January 2, 2019. Main pilot trains will continue operating until March 31, 2019, although the operation of mini pilot columns may be halted prior to this time, depending on when PFAS breakthrough is observed. The GAC and IX main pilot trains will be operated in parallel for the entire duration of the project. Over the duration of the project, it is anticipated that the main pilot trains will operate at three different flow rates to evaluate PFAS removal at different empty bed contact times (EBCT). Mini pilot columns will be in operation at a constant flow rate until PFAS breakthrough is achieved. The main pilot columns will have a sample ports at different depths media depths to evaluate removal and breakthrough along the media depth.

Routine field water quality analyses will be conducted by The Authority, and PFAS, compounds of emerging concern (CECs) and other non-routine (e.g. disinfection by-products, metals, etc.) samples will be collected by Catlin Engineers and Scientists (Catlin). GEL Laboratories (GEL) will conduct the PFAS analyses, and Eurofins Eaton Analytical (Eurofins) will conduct the CEC and non-routine compound analyses. A summary of parameters and sampling frequencies is presented in the Test Monitoring Section of this Test Plan. A complete list of PFAS, CECs, and non-routine compounds is presented in Appendix B.

Equipment Procurement and Setup

In accordance with General Assembly of North Carolina Session 2017, Session Law 2018-5, Senate Bill 99, the Authority is to test the effectiveness of ion exchange and activated carbon technologies for treatment of PFAS, including GenX. The Senate bill established the following: (i) install temporary ion exchange and carbon treatment systems suitable to treat 500 gallons per minute (gpm) flow as a minimum capacity; (ii) after installation of the temporary treatment systems, test the water treated weekly, before and after treatment by ion exchange and activated carbon, over a period of six weeks at increasing flow rates to determine the relative effectiveness of the two technologies at reducing PFAS, including GenX, and (iii) after determination of the most successful treatment technology at a high flow of 500 gpm, continue sampling water treated by the technology at two week intervals thereafter.

This study will be performed by operating one GAC main pilot train and one IX main pilot train in parallel to compare the two alternatives for PFAS removal. Both main pilot trains will be supplied by the same contractor, Water and Waste Systems Construction, Inc., who was selected based on the lowest responsible bid. The contractor's equipment vendor, Calgon, Inc., will provide onsite service during start-up of the main pilot trains and mini pilot columns.

The existing ASR pump has an approximate capacity of 700 gpm. Therefore it is not possible to operate both pilots at 500 gpm. There is also concern that it will not be possible to determine the most successful technology after a period of six weeks as breakthrough is not likely to occur for many of the constituents and each technology may perform differently with respect to specific



contaminants. Therefore, it is recommended that both main pilot trains operate under the same conditions at all times, up to a flow rate of 250 gallons per minute (gpm) per train. It is not expected that backwashing will need to be performed during testing due to the relatively short time frame, and treated pilot effluent will be discharged to the sanitary sewer. Mini pilot columns will be used as a small scale pilot to simulate full-scale operations and test PFAS breakthrough at a constant flow rate.

Given the relatively short study timeframe, it is possible that the main pilot trains will not see complete breakthrough of specific PFAS compounds prior to the completion of this study. Sample ports at 25%, 50%, 75% and 100% media bed depths are proposed on both the GAC and IX main pilot trains to determine breakthrough patterns within the vessels. Additionally, GAC and IX mini pilot columns will be evaluated to ensure complete breakthrough is observed and results will be scaled up appropriately to estimate full-scale PFAS breakthrough. These mini pilot columns will be supplied by the same vendor who is providing the main pilot trains The mini pilot columns will be 4-inches in diameter. A schematic of mini pilot columns is depicted in Figure 1. Three mini pilot column configurations will be tested: one GAC column (column 1, shown in blue), one IX column (column 2, shown in green), and one lead-lag (GAC-IX) column configuration (columns 3 and 4, shown in yellow). Mini pilot columns will be located inside of the existing water tower at the Westbrook ASR well site, and mini pilot column influent will come from the same common pipeline that is used to supply the two main pilot trains.




Figure 1. Mini Pilot Column Configuration

Main pilot train flow rates will be periodically increased throughout the duration of this study to evaluate the removal of PFAS at multiple EBCTs since research has shown that increased EBCTs often result in increased constituent removal. It is estimated that main pilot train GAC media capacity will be 300 ft³ and IX resin capacity will be 100 ft³ based on information obtained the GAC and IX vendor. Previous research has recommended GAC EBCTs ranging from 10 minutes to 20 minutes and IX EBCTs ranging from 2 minutes to 4 minutes for PFAS removal. Flow rates and EBCTs in the main pilot trains will be evaluated sequentially as shown in Table 2. As shown in Table 2 and Table 4, it is anticipated that main pilot train flow rate will start at 130 gpm for the first two weeks, then be increased to 175 gpm for an additional two weeks. A final increase in flow rate to 250 gpm per main pilot train will occur during week 5, which will remain constant for the remainder of this investigation (through week 13), for a total operation time of 9 weeks at 250 gpm. Changes in flow rate will be modified as deemed necessary based



on results. Although it is not expected that breakthrough will be observed at the 100% bed depth during the first few weeks at the lower feed rate, breakthrough will be tracked through the bed, and results obtained from intermediate sampling ports will be used to compare the impact of EBCTs on PFAS removal.

GAC and IX mini pilot columns will consistently operate at EBCTs of 10 minutes and 2 minutes, respectively. 4-inch diameter mini pilot columns previously used for the Sweeney WTP pilot will be relocated to the ASR site.

Table 2. GAC and IX EBCTs to be Evaluated for Main Pilot Train Demonstration

Flow Rate (gpm) ^a	GAC EBCT (min)	IX EBCT (min)	No. Weeks ^a
130	20	4	2
175	15	3	2
250	10	2	9

^aSubject to change based on preliminary results.

Test Monitoring

Routine water quality monitoring will be performed on samples collected from a common influent sample port in addition to GAC and IX main pilot train effluent sample ports and mini pilot columns. Collected hydraulic and water quality data will be input into project data monitoring templates by the Project Team on a weekly basis. Field parameters routinely collected will be provided to HDR by the Authority weekly. Results from samples analyzed by an external lab will be provided as soon as they are available. Table 3 presents a list monitoring parameters, monitoring frequency, and the entity/lab responsible for sample collection and analysis. Many parameters in Table 3 are already monitored in the Authority's ASR system, including flow rate, water level/pressure, cumulative volume, pH, temperature, dissolved oxygen, and redox potential.

PFAS samples will be collected once per week, and a suite of 41 PFAS will be tested. Individual PFAS analyzed in this study are presented in Appendix B. Daily monitoring of total organic carbon (TOC) and TOC's surrogate, UV absorbance at 254 nm (UV254), can provide invaluable information regarding breakthrough of the main pilot trains. For example, if TOC is monitored daily in mini pilot columns and breakthrough is observed after a given period of time, this information can be used to predict when TOC and PFAS breakthrough will occur in the main pilot trains. The pattern of TOC breakthrough relative to PFAS breakthrough in the mini pilot columns can be applied to the main pilot trains to help predict when PFAS breakthrough can be expected. This would allow PFAS sampling to be conducted at the appropriate media depths after the appropriate run time.



Table 3. Sampling Plan - Main Pilot Trains

Parameter	Frequency	Entity/Lab
Flow Rate	Continuous/Daily ^b	Authority
Water Level/Pressure	Continuous/Daily ^b	Authority
Cumulative Volume	Continuous/Daily ^b	Authority
pH	Daily	Authority
Temperature	Daily	Authority
Dissolved Oxygen	Daily	Authority
Conductivity	Daily	Authority
Total Organic Carbon	3 x Week	Authority/Eurofins
UV254	3 x Week	Authority/Eurofins
Redox Potential	1 x Week	Authority
Turbidity	1 x Week	Authority
Alkalinity	1 x Week	Authority/Eurofins
Hardness	1 x Week	Authority/Eurofins
Total Dissolved Solids	1 x Week	Authority/Eurofins
Iron	1 x Week	Authority/Eurofins
Manganese	1 x Week	Authority/Eurofins
PFAS°	1 x Week	Catlin/GEL
CECs and non-routine compounds ^c	Weeks 1, 7 and 13	Catlin/Eurofins

^aParameters evaluated daily should be monitored around the same time each day. Parameters evaluated weekly should be evaluated on the same day each week. The date and time of initial pilot startup and all sample collection shall be recorded along with any interference with treatment process due to shutdowns, significant increase or drop in flow rate, etc. ^bContinuously monitored parameters will be manually checked daily using the appropriate gauges/meters to ensure the instrumentation is operating correctly. ^cA complete list of PFAS, CECs, and non-routine compounds is presented in Appendix B.

Analytical Cost Considerations and Sampling Schedule

The current budget for PFAS testing at an external laboratory is \$65,000, and the cost to test one PFAS sample (including the entire suite of 41 PFAS) is \$450.50. This allows 144 PFAS samples to be collected throughout this study. Samples will be collected at the following sample ports, although collection at each sample port will not occur during each sampling event:

- 1. Influent
- 2. GAC main pilot train effluent 25% bed depth
- 3. GAC main pilot train effluent 50% bed depth
- 4. GAC main pilot train effluent 75% bed depth
- 5. GAC main pilot train effluent 100% bed depth
- 6. IX main pilot train effluent 25% bed depth
- 7. IX main pilot train effluent 50% bed depth
- 8. IX main pilot train effluent 75% bed depth
- 9. IX main pilot train effluent 100% bed depth
- 10. GAC mini pilot column 1 effluent
- 11. IX mini pilot column 2 effluent
- 12. GAC mini pilot column 3 effluent (column 4 influent)
- 13. IX mini pilot column 4 effluent



Available PFAS sampling funds cannot cover sample collection from each location over the course of this study, and sampling each port throughout the entire duration of the study is not necessary. PFAS breakthrough in mini pilot columns is expected to occur early on in the study; therefore, collecting samples from mini pilot columns may not be necessary for the entire duration of the project. Table 4 presents the proposed PFAS sample collection schedule. This schedule results in 135 samples collected from various points throughout the main pilot trains and mini pilot columns, allowing 9 additional samples to be collected from locations or at frequencies that have yet to be determined. Sample collection locations and frequencies in the main pilot trains are subject to change based on breakthrough patterns observed in the mini pilot columns. If additional samples are needed elsewhere (e.g. if it is decided that the 75% bed depth should be sampled numerous times from both main pilot trains, exceeding the 9 allotted additional samples), sampling the lead column in the GAC-IX lead-lag configuration (column 3) will be reduced, as results should be the same as those observed in column 1. As previously mentioned, flow rates/EBCTs are subject to change based on preliminary PFAS results.

There are over 150 non-regulated CECs and non-routine compounds that could be sampled during this project, and testing the entire suite of parameters costs around \$4,200 per sample; therefore, it is most cost-effective to only sample for compounds that are of concern or of potential concern at the ASR well. There is initially \$50,000 available for CEC testing. It is recommended that only CECs detected above the reporting limit during previous background testing be tested in the influent and GAC and IX main pilot train effluents during this study. Background testing results are presented in Appendix B.

Sampling for TOC and UV254 will occur three times per week for the duration of this project from seven sample ports: influent, GAC main pilot train effluent, IX main pilot train effluent, and the four mini pilot columns. This results in 273 total TOC and UV254 samples for this project, resulting in a total estimated cost of \$23,205 for external laboratory analyses. Additional parameters, including alkalinity, hardness, total dissolved solids, iron, and manganese will be collected once per week from the same seven sample ports and shipped to Eurofins for analyses. It is estimated that sampling for these parameters will result in a total cost \$23,205 for this project. Data will be evaluated on an ongoing basis to determine if the frequency of analysis should be changed during the course of the study. Additional parameters, including alkalinity, hardness, total dissolved solids, iron, and manganese will be collected once per week from the same seven sample ports and shipped to Eurofins for analyses.



Table 4. Proposed PFAS Sampling Schedule

							Week						
	1/8/19- 1/13/19	1/14/19- 1-20/19	1/21/19- 1/27/19	1/28/19- 2/3/19	2/4/19- 2/10/19	2/11/19- 2/17/19	2/18/19- 2/24/19	2/25/19- 3/3/19	3/4/19- 3/10/19	3/11/19- 3/17/19	3/18/19- 3/24/19	3/25/19- 3/31/19	4/1/19- 4/7/19
Sample Location	1	2	3	4	5	6	7	8	9	10	11	12	13
	Main Pilot Train Flow Rate (gpm per train)												
	130	130	175	175	250	250	250	250	250	250	250	250	250
	00/4	00/4	15/0				GAC/IX		_		10/0	10/0	10/0
	20/4	20/4	15/3	15/3	10/2	10/2	10/2	10/2	10/2	10/2	10/2	10/2	10/2
Influent	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
GAC Main Pilot Train Effluent – 25%	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Χ	Χ	Х
IX Main Pilot Train Effluent – 25%	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
GAC Main Pilot Train Effluent – 50%	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
IX Main Pilot Train Effluent – 50%	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
GAC Main Pilot Train Effluent – 75%	As Needed												
IX Main Pilot Train Effluent – 75%						As	s Need	ed					
GAC Main Pilot Train Effluent – 100%	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
IX Main Pilot Train Effluent – 100%	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
GAC Mini Pilot Column Effluent (col. 1)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		
IX Mini Pilot Column Effluent (col. 2)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		
GAC Mini Pilot Column Effluent (col. 3)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		
IX Mini Pilot Column Effluent (col. 4)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		

^{*}It is assumed that mini pilot columns will reach breakthrough in less than 10 weeks; therefore sampling for the entire duration of the project may not be necessary. The mini pilot columns will be operated at constant flow rate (250 gpm) throughout the duration of the study at EBCTs of 20 and 4 minutes for GAC or IX, respectively. The 75% bed depth will be sampled as needed based on preliminary results. Flow rates/EBCTs are subject to change based on preliminary results.





Appendix A – Baseline PFAS Results from the Westbrook ASR Well

Table A-1 presents PFAS results from a baseline study using samples collected from the ASR well in July 2018. In this analysis, 12 out of 41 PFAS were above reporting limits. The highest PFAS concentration was 404 ng/L for perfluoro-2-methoxyacetic acid (PFMOAA).

Table A-1. Baseline PFAS Results from the Westbrook ASR Well

Analyte	Concentration (ng/L)		
11-chloroeicosafluoro-3-oxaundecane-1-sulfonate (F-53B Minor)	ND		
2,3,3,3-Tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)-propanoic acid (PFPrOPrA, GenX)	37.7		
2-(N-ethylperfluoro-1-octanesulfonamido)-ethanol (N-EtFOSE)	ND		
2-(N-methylperfluoro-1-octanesulfonamido)-ethanol (N-MeFOSE)	ND		
9-chlorohexadecafluoro-3-oxanonane-1-sulfonate	ND		
Fluorotelomer sulfonate 10:2 (10:2 FTS)	ND		
Fluorotelomer sulfonate 6:2 (6:2 FTS)	ND		
Fluorotelomer sulfonate 8:2 (8:2 FTS)	ND		
N-ethylperfluoro-1-octanesulfonamide (N-EtFOSA)	ND		
N-ethylperfluoro-1-octanesulfonamidoacetic acid (N-EtFOSAA)	ND		
N-methylperfluoro-1-octanesulfonamide (N-MeFOSA)	ND		
N-methylperfluoro-1-octanesulfonamidoacetic acid (N-MeFOSAA)	ND		
Perfluorobutanesulfonate (PFBS)	ND		
Perfluorodecanesulfonate (PFDS)	ND		
Perfluorodecanoic acid (PFDA)	ND		
Perfluorododecanoic acid (PFDoA)	ND		
Perfluoroheptanesulfonate (PFHpS)	ND		
Perfluoroheptanoic acid (PFHpA)	2.22		
Perfluorohexanesulfonate (PFHxS)	ND		
Perfluorohexanoic acid (PFHxA)	2.90		
Perfluorononanesulfonate (PFNS)	ND		
Perfluorononanoic acid (PFNA)	ND		
Perfluorooctanesulfonamide (PFOSA)	ND		
Perfluorooctanesulfonate (PFOS)	3.92		
Perfluorooctanoic acid (PFOA)	2.58		
Perfluoropentanesulfonate (PFPeS)	ND		
Perfluorotetradecanoic acid (PFTeDA)	ND		
Perfluorotridecanoic acid (PFTrDA)	ND		
Perfluoroundecanoic acid (PFUdA)	ND		
Sodium dodecafluoro-3H-4,8-dioxanonanoate (ADONA)	ND		
Fluorotelomer sulfonate 4:2 (4:2 FTS)	ND		
Perfluorobutyric acid (PFBA)	ND		
Perfluoropentanoic acid (PFPeA)	6.06		
Nafion Byproduct 1*	ND		
Nafion Byproduct 2*	6.15		
Perfluoro(3,5,7,9-tetraoxadecanoic) acid (PFO4DA)*	30.7		
Perfluoro(3,5-dioxahexanoic) acid (PFO2HxA)*	365		



Analyte	Concentration (ng/L)
Perfluoro-2-methoxyacetic acid (PFMOAA)*	404
Perfluoro-3-methoxypropanoic acid (PFMOPrA)*	8.63
Perfluoro-4-methoxybutanic acid (PFMOBA)*	ND
Perfluoro(3,5,7-trioxaoctanoic) acid (PFO3OA)*	141

ND = not detected.

PFAS and CECs Analyzed



Appendix B – PFAS and CECs

PFAS that will be analyzed are presented in Table B-1. PFAS samples will be collected by Catlin and analyzed by GEL using EPA Method 537. Compounds in bold were detected in the baseline study previously presented in Appendix A.

Table B-1. PFAS Analyzed

PFAS	Abbreviation
11-chloroeicosafluoro-3-oxaundecane-1-sulfonate	F-53B Minor
2,3,3,3-Tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)-propanoic acid	PFPrOPrA, GenX
2-(N-ethylperfluoro-1-octanesulfonamido)-ethanol	N-EtFOSE
2-(N-methylperfluoro-1-octanesulfonamido)-ethanol	N-MeFOSE
9-chlorohexadecafluoro-3-oxanonane-1-sulfonate	No abbreviation
Fluorotelomer sulfonate 10:2	10:2 FTS
Fluorotelomer sulfonate 4:2	4:2 FTS
Fluorotelomer sulfonate 6:2	6:2 FTS
Fluorotelomer sulfonate 8:2	8:2 FTS
N-ethylperfluoro-1-octanesulfonamide	N-EtFOSA
N-ethylperfluoro-1-octanesulfonamidoacetic acid	N-EtFOSAA
N-methylperfluoro-1-octanesulfonamide	N-MeFOSA
N-methylperfluoro-1-octanesulfonamidoacetic acid	N-MeFOSAA
Nafion Byproduct 1 ^a	No abbreviation
Nafion Byproduct 2 ^a	No abbreviation
Perfluoro(3,5,7,9-tetraoxadecanoic) acid ^a	PFO4DA
Perfluoro(3,5,7-trioxaoctanoic) acid ^a	PFO3OA
Perfluoro(3,5-dioxahexanoic) acid ^a	PFO2HxA
Perfluoro-2-methoxyacetic acid ^a	PFMOAA
Perfluoro-3-methoxypropanoic acida	PFMOPrA
Perfluoro-4-methoxybutanic acida	PFMOBA
Perfluorobutanesulfonate	PFBS
Perfluorobutyric acid	PFBA
Perfluorodecanesulfonate	PFDS
Perfluorodecanoic acid	PFDA
Perfluorododecanoic acid	PFDoA
Perfluoroheptanesulfonate	PFHpS
Perfluoroheptanoic acid	PFHpA
Perfluorohexanesulfonate	PFHxS
Perfluorohexanoic acid	PFHxA
Perfluorononanesulfonate	PFNS
Perfluorononanoic acid	PFNA
Perfluorooctanesulfonamide	PFOSA
Perfluorooctanesulfonate	PFOS
Perfluorooctanoic acid	PFOA
Perfluoropentanesulfonate	PFPeS
Perfluoropentanoic acid	PFPeA
Perfluorotetradecanoic acid	PFTeDA
Perfluorotridecanoic acid	PFTrDA
Perfluoroundecanoic acid	PFUdA
Sodium dodecafluoro-3H-4,8-dioxanonanoate	ADONA

^aCompounds do not have certified standards.



Table B-2 presents CECs and non-routine water quality parameters that will be analyzed in an initial screening of the ASR system. Non-routine parameters include constituents that are not frequently tested in water treatment, but are not necessarily CECs (e.g. chlorite, chlorate, disinfection by-products, metals, etc.). These compounds will be collected by Catlin and analyzed by Eurofins using liquid chromatography with tandem mass spectrometry (LC/MS/MS). Compounds in bold were detected in samples collected in 2012 and/or 2013.

Table B-2. CECs and Non-Routine Compounds Analyzed

Group Name	Individual Compounds
1,4-Dioxane	1,4-Dioxane
Bromide, Chlorate, Chlorite	Bromide, Chlorate, Chlorite
Carbamates	1-Naphthol
	Aldicarb
	Aldicarb sulfoxide
	Carbofuran
	Oxamyl
	3-Hydroxycarbofuran
	Aldicarb sulfone
	Cararyl
	Methomyl
Chlorinated Acids	Dinoseb
	2,4-D
	Pecloram
	Pentachlorophenol
	Dalapon
	2,4,5-TP (Silvex)
Total Cyanide	Total Cyanide
Diquat	Diquat
EDB/DBCP	1,2-Dibromoethane
	1,2-Dibromo-3-chloropropane
EDCs, PPCPs, Hormones	1,7-Dimethylxanthine
	17alpha-Ethynyl estradiol
	17beta-Estradiol
	2,4-D
	4-Androstene
	4-Nonylphenol
	4-tert-Octylphenol
	Acesulfame-K
	Acetaminophen
	Albuterol
	Amoxicillin
	Antipyrine
	Atenolol
	Atrazine
	Azithromycin
	Bendroflumethiazide
	Bezafibrate
	Bisphenol A



Group Name	Individual Compounds
	Bromacil
	Butalbital
	Butylparaben
	Caffeine
	Carbadox
	Carbamazepine
	Carisoprodol
	Chloramphenicol
	Chloridazon
	Chlorotoluron
	Cimedtidine
	Clofibric acid
	Cotinine
	Cyanazine
	DEET
	Dehydronifedipine
	Desethylatrazine
	Desisopropylatrazine
	Diaminochlorotriazine
	Diazepam
	Diclofenac
	Dilantin
	Diltiazem
	Diruon
	Erythromycin
	Estriol
	Estrone
	Ethylparaben
	Flumequine Fluoxetine (Prozac)
	Gemfibrozil
	Ibuprofen lohexal
	lopromide
	Isobutylparaben
	Isoproturon
	Ketoprofen
	Ketorolac
	Lidocaine
	Lincomycin
	Linuron
	Lopressor
	Meclofenamic acid
	Meprobamate
	Metazochlor
	Methylparaben
	Metolachlor
	Naproxen
	Nifedipine



Group Name	Individual Compounds
Group Name	Norethisterone
	Oxolinic acid
	Pentoxifylline
	Primidone
	Progesterone
	Propazine
	Propylparaben
	Quinoline
	Salicylic Acid
	Simazine
	Sucralose
	Sulfachloropyridazine
	Sulfadiazine
	Sulfadimethoxine
	Sulfamerazine
	Sulfamethazine
	Sulfamethizole
	Sulfamethoxazole
	Sulfathiazole
	Sulfometruon Methyl
	Testosterone
	Theobromine
	Theophylline
	Thiabendazole
	Triclocarban
	Triclosan
	Trimethoprim
	Tris(1,3-dichloro-2-propyl) phosphate
	Tris(2-carboxyethyl)phosphine hydrochloride Warfarin
En de de ell	
Endothall	Endothall Class Care Care Care Care Care Care Care Care
Fluoride, Chloride, Nitrate, Sulfate	Fluoride, Chloride, Nitrate, Sulfate
Glyphosate	Glyphosate
Gross Alpha & Beta	Gross Alpha
	Gross Beta
Haloacetic Acids	Dibromoacetic Acid
	Dichloroacetic Acid
	Monobromoacetic Acid
	Monochloracetic Acid
	Trichloroacetic Acid
Metals – ICP AES	Sodium
	Total Silica
	Potassium
	Magnesium
	Calcium
Metals – ICP MS	Aluminum
	Antimony
	Arsenic



Group Name	Individual Compounds
	Beryllium
	Boron
	Cadmium
	Chromium
	Cobalt
	Copper
	Lead
	Lithium
	Manganese
	Molybdenum
	Nickel
	Selenium
	Silver
	Strontium
	Thallium
	Thorium
	Tin
	Titanium
	Uranium
	Vanadium
14	Zinc
Mercury	Mercury
Nitrogen, Ammonia	Nitrogen, Ammonia
Perchlorate	Perchlorate
Phase II & V	Di(2-ethylhexyl)adipate
	Hexachlorobenzene
	Heptachlor epoxide
	Endrin
	Di(2-ethylhexyl)phthalate
	Alachlor
	Hexachlorocyclopentadiene
	Simazine
	Gamma-BHC (Lindane)
	Atrazine
	Heptachlor
	Methoxychlor
B)	Benzo(a)pyrene
Phase II & V	Aroclor 1016
PCB/Toxaphene/Chlordane	Aroclor 1221
	Aroclor 1232
	Aroclor 1242
	Aroclor 1248
	Aroclor 1254
	Aroclor 1260
	Chlordane
	Toxaphene
Radium-226	Radium-226
Radium-228	Radium-228 RC Uranium
RC Uranium	



Group Name	Individual Compounds
Trihalomethanes	Bromodichloromethane
	Bromoform
	Chloroform
	Dibromochloromethane
LTB/VOCs	Tetrachloroethylene
	Toluene
	Trichloroetylene
	Vinyl Chloride
	Trans-1,2-Dichloroethylene
	Carbon Tetrachloride
	Chlorobenzene
	Benzene
	1,1-Dichloroethylene
	Dichloromethane
	1,4-Dichlorobenzene
	1,3+1,4-Xylene
	Cis-1,2-Dichloroethylene
	Ethylbenzene
	1,2-Xylene
	1,2-Dichloropropane
	1,1,2-Trichloroethane
	1,2-Dichloroethane
	Epichlorohydrin
	1,2-Dichlorobenzene
	1,1,1-Trichloroethane
VOCs	Cis-1,2-Dichloroethylene
	Trans-1,2-Dichloroethylene
	Carbon Tetrachloride
	1,4-Dichlorobenzene
	1,2,4-Trichlorobenzene
	1,1,2-Trichloroethane
	1,2-Xylene
	Ethylbenzene
	Styrene
	Tetrachloroethylene
	Toluene
	Trichloroethylene
	Vinyl Chloride
	Benzene
	Chlorobenzene
	1,2-Dichloroethane
	Epichlorohydrin
	1,3+1,4-Xylene
	1,2-Dichloropropane
	Dichloromethane
	1,2-Dichlorobenzene
	1,1,1-Trichloroethane
	1,1-Dichloroethylene